Brad Schenkel, MS
Director, HECOR Oncology
Janssen Scientific Affairs, LLC
Health Economics and Outcomes Research
800 Ridgeview Drive
Horsham,
PA
USA
19044
Email:
bschenk9@its.jnj.com
Biographical Sketch: Currently, I am the Director, Health Economics and Outcomes Research for the Oncology and Immunology Franchises for Johnson & Johnson. My responsibilities include Health Economics project leadership for ibrutinib and ustekinumab across indications, Leader for Site of Care strategy development and evidence generation, as well as the establishment of Quality Measures for REMICADE, STELARA, and SIMPONI in the context of US health care reform.
Previously, I worked on preparing and establishing market access/reimbursement for dermatology product across all Johnson & Johnson operating companies. I was also involved with developing and implementing the global pricing and reimbursement strategy and communicating the value proposition for VELCADE and EPREX in partnership with internal colleagues in all ex-US territories.
Papers:
DEVELOPMENT OF AN ONLINE PATIENT DECISION AID FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA
PATIENT AND HEALTHCARE PROVIDER INVOLVEMENT IN THE DEVELOPMENT OF A PATIENT DECISION AID FOR THOSE WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA